CO2022018811A2 - Inhibidores de la proteína kras g12c y usos de estos - Google Patents

Inhibidores de la proteína kras g12c y usos de estos

Info

Publication number
CO2022018811A2
CO2022018811A2 CONC2022/0018811A CO2022018811A CO2022018811A2 CO 2022018811 A2 CO2022018811 A2 CO 2022018811A2 CO 2022018811 A CO2022018811 A CO 2022018811A CO 2022018811 A2 CO2022018811 A2 CO 2022018811A2
Authority
CO
Colombia
Prior art keywords
kras
protein inhibitors
compounds
pharmaceutical compositions
administration
Prior art date
Application number
CONC2022/0018811A
Other languages
English (en)
Inventor
Bo Shan
Jian Wang
Bing Hou
Zhongyang Shi
Peng Chen
Hui Yuwen
Xingquan Ma
Zhu Du
Jay Mei
Original Assignee
Antengene Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Discovery Ltd filed Critical Antengene Discovery Ltd
Publication of CO2022018811A2 publication Critical patent/CO2022018811A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Abstract

La presente divulgación se refiere a compuestos novedosos útiles como inhibidores de la proteína KRAS, así como a composiciones farmacéuticas que comprenden estos compuestos y métodos de tratamiento mediante la administración de estos compuestos o las composiciones farmacéuticas.
CONC2022/0018811A 2020-06-04 2022-12-23 Inhibidores de la proteína kras g12c y usos de estos CO2022018811A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020094307 2020-06-04
CN2021075503 2021-02-05
CN2021090216 2021-04-27
CN2021096134 2021-05-26
PCT/CN2021/098083 WO2021244603A1 (en) 2020-06-04 2021-06-03 Inhibitors of kras g12c protein and uses thereof

Publications (1)

Publication Number Publication Date
CO2022018811A2 true CO2022018811A2 (es) 2022-12-30

Family

ID=78830123

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018811A CO2022018811A2 (es) 2020-06-04 2022-12-23 Inhibidores de la proteína kras g12c y usos de estos

Country Status (11)

Country Link
US (1) US20230212170A1 (es)
EP (1) EP4161934A1 (es)
JP (1) JP2023528903A (es)
KR (1) KR20230019855A (es)
CN (1) CN115836072A (es)
AU (1) AU2021283585A1 (es)
CA (1) CA3182507A1 (es)
CO (1) CO2022018811A2 (es)
IL (1) IL298670A (es)
MX (1) MX2022015272A (es)
WO (1) WO2021244603A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
AR126166A1 (es) * 2021-06-18 2023-09-27 Antengene Discovery Ltd Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CN114409653A (zh) * 2021-12-31 2022-04-29 苏州闻天医药科技有限公司 一种桥环并嘧啶并环类化合物及其用途
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710439B1 (en) * 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW201942116A (zh) * 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
MA51777A (fr) * 2018-08-16 2021-04-21 Hoffmann La Roche Composés cycliques condensés
JP2022500385A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN112390788A (zh) * 2019-08-13 2021-02-23 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
WO2021037018A1 (zh) * 2019-08-26 2021-03-04 南京创济生物医药有限公司 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CN112830928A (zh) * 2019-11-22 2021-05-25 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
WO2021139678A1 (zh) * 2020-01-07 2021-07-15 广州百霆医药科技有限公司 吡啶并嘧啶类kras g12c突变蛋白抑制剂

Also Published As

Publication number Publication date
MX2022015272A (es) 2023-01-11
US20230212170A1 (en) 2023-07-06
CN115836072A (zh) 2023-03-21
IL298670A (en) 2023-01-01
AU2021283585A1 (en) 2022-11-17
CA3182507A1 (en) 2021-12-09
WO2021244603A1 (en) 2021-12-09
EP4161934A1 (en) 2023-04-12
KR20230019855A (ko) 2023-02-09
JP2023528903A (ja) 2023-07-06

Similar Documents

Publication Publication Date Title
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CO2021005987A2 (es) Compuestos de anillo fusionado
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
ECSP19076732A (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201892207A1 (ru) Индолкарбоксамидные соединения
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA202192433A1 (ru) Соединения, полезные в терапии вич
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CO2021011042A2 (es) Sales de sulcardina
CL2023000772A1 (es) Compuestos heterocíclicos de heteroarilo y usos de los mismos
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
EA201691878A1 (ru) ИНГИБИТОРЫ СИГНАЛЬНЫХ ПУТЕЙ Wnt
CO2023000858A2 (es) Inhibidores de atr y usos de estos